|
|
Evolutions in the Management of Duchenne Muscular Dystrophy (DMD): Treatment Implications for the Present and Future
Target Audience
This educational activity is intended for healthcare professionals involved in the management of patients with Duchenne Muscular Dystrophy (DMD), including neurologists, neuromuscular specialists, and other members of the healthcare team who care for patients with DMD.
Program Overview
Duchenne muscular dystrophy (DMD) impacts 1 in every 3,500 male births globally, and its progression is both relentless and fatal. However, the rapid advancement in DMD therapies brings hope... |
|
|
Improving the Management of Patients With Duchenne Muscular Dystrophy: Emerging Evidence and Treatment Strategies
Target Audience
This activity is designed to meet the educational needs of health care professionals involved in the management of patients with Duchenne muscular dystrophy (DMD), including neurologists and other neuromuscular specialists, with a portion targeting pediatricians.
Program Overview
Expand your knowledge of DMD by exploring real patient case reviews! Gain a deeper understanding of dystrophin’s role in disease progression, explore the latest clinical trial results across tre... |
|
|
Extending Dosing Intervals in Retinal Disease: Patient Perspectives and Clinical Insights to Guide Your Practice
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are increasingly prevalent retinal diseases that pose significant challenges in ophthalmic care. While anti-vascular endothelial growth factor (VEGF) therapies have greatly improved visual outcomes for patients with these conditions, real-world data indicate that many patients receive suboptimal treatment and monitoring, resulting in poorer visual outcomes. Newer therapeutic options have been developed to exte... |
|
|
Nutraceuticals for Dry Eye: Dispelling the Dogma and Embracing the Data
Dry eye disease is a common yet frequently overlooked condition that significantly affects quality of life. Despite an estimated global prevalence of up to 50%, DED is often underdiagnosed and inadequately managed. To limit the burden of DED, it is crucial for clinicians to be adept at recognizing risk factors and making accurate diagnoses. In addition, as treatment options expand to include clinically proven nutraceuticals, it is imperative that clinicians stay abreast of the latest clinical ... |
|